Abstract
The aim of this study was to evaluate the cardiovascular and renal activities of a newly designed natriuretic peptide (NP). Here, we engineered a novel 28-amino acid chimeric peptide, termed AC-NP that combined the 17-amino acid ring of C type natriuretic peptide (CNP) with the 6-amino acid N-terminus and 5-amino acid C-terminus of atrial natriuretic peptide (ANP). Both in vitro and in vivo experiments were performed to determine the actions of AC-NP. In normal rats, AC-NP proved to be more potentially diuretic, natriuretic and hypotensive compared with other NPs, such as ANP, CNP and vasonatrin peptide (VNP), which is another man-made NP. In relaxation of isolated abdominal aorta from rat, AC-NP was equally effective to ANP, CNP and VNP. Elevated levels of 3′,5′-guanosine monophosphate (cGMP) in plasma and urine cGMP excretion indicated the participation of cGMP in the functions of AC-NP. Taken together, innovative designed AD-NP might be a new candidate therapeutic peptide against cardiorenal disorders. © 2011 Chen et al.
Cite
CITATION STYLE
Chen, B. Y., Chen, J. K., Zhu, M. Z., Zhang, D. L., Sun, J. S., Pei, J. M., … Yu, J. (2011). AC-NP: A novel chimeric peptide with natriuretic and vasorelaxing actions. PLoS ONE, 6(5). https://doi.org/10.1371/journal.pone.0020477
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.